Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi

• Published in: Diabetes therapy Vol. 10; no. 2; pp. 493 - 508
• Main Authors: Pöhlmann, Johannes, Russel-Szymczyk, Monika, Holík, Pavel, Rychna, Karel, Hunt, Barnaby
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01-04-2019; Springer; Springer Nature B.V
• Subjects: Cardiology; Comparative analysis; Cost analysis; Cost control; Diabetes; Diabetes therapy; Dosage and administration; Drug therapy; Economic aspects; Endocrinology; Glucose monitoring; Insulin; Internal Medicine; Life expectancy; Medicine; Medicine & Public Health; Original Research; Patient outcomes; Patients; Pharmacology, Experimental; Physiological aspects; Sensitivity analysis; Type 2 diabetes; Czech Republic; Type 2 diabetes; Czech Republic; Fixed-ratio combination; iGlarLixi; Cost-effectiveness; IDegLira
• ISSN: 1869-6953; 1869-6961
• DOI: 10.1007/s13300-019-0569-7

Introduction
Few patients with type 2 diabetes mellitus (T2DM) achieve recommended glycemic control targets in the Czech Republic. Novel therapies, such as fixed-ratio combinations of basal insulin plus glucagon-like peptide-1 receptor agonists, may contribute to better glycemic control. In the analysis presented here, the present analysis assessed the long-term cost-effectiveness of two fixed-ratio combinations, IDegLira (insulin degludec/liraglutide) and iGlarLixi (insulin glargine/lixisenatide), for the treatment of patients with T2DM inadequately controlled with basal insulin from a healthcare payer perspective in the Czech Republic.
Methods
A cost-effectiveness analysis was performed over patient lifetimes using the IQVIA CORE Diabetes Model. Treatment effects were obtained from an indirect treatment comparison as no head-to-head data for IDegLira versus iGlarLixi are currently available. IDegLira was compared with two iGlarLixi pens (100 U/mL insulin glargine + 33 μg/mL and 50 μg/mL of lixisenatide, respectively). Direct medical costs associated with pharmaceutical interventions, screening and diabetes-related complications were captured. Deterministic and probabilistic sensitivity analyses were performed.
Results
IDegLira was associated with gains in life expectancy of 0.11 years and in quality-adjusted life expectancy of 0.14 quality-adjusted life-years (QALYs) versus iGlarLixi, due to a lower cumulative incidence and delayed onset of diabetes-related complications. IDegLira was also associated with higher projected costs due to higher acquisition costs; however, these were partially offset by cost savings from avoided complications. IDegLira was associated with incremental cost-effectiveness ratios of Czech Koruna (CZK) 695,998 and CZK 348,323 per QALY gained versus iGlarLixi pens containing 33 and 50 μg/mL of lixisenatide, respectively. These ratios were below the commonly used willingness-to-pay threshold of CZK 1,200,000 per QALY gained.
Conclusion
The present analysis indicated that IDegLira was associated with clinical benefits relative to iGlarLixi over patient lifetimes and was likely to be cost-effective in the treatment of patients with T2DM uncontrolled on basal insulin in the Czech Republic.
Funding
Novo Nordisk.
Plain Language Summary
Plain language summary is available for this article.